# Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

> **NCT05561686** · — · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 100 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT05561686
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-10-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561686, "Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05561686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*